# Focused Orticumab Research for Treating Inflammation in Coronary Arteries

> **NCT06927739** · PHASE2 · RECRUITING · sponsor: **Abcentra** · enrollment: 240 (estimated)

## Conditions studied

- Acute Coronary Syndromes
- Coronary Arterial Disease (CAD)
- Inflammation
- Heart Disease
- Myocardial Infarct
- Atherosclerotic Coronary Vascular Disease

## Interventions

- **DRUG:** Orticumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06927739
- **Lead sponsor:** Abcentra
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-11
- **Primary completion:** 2027-02-08
- **Final completion:** 2027-06-01
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06927739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06927739, "Focused Orticumab Research for Treating Inflammation in Coronary Arteries". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT06927739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*